377 related articles for article (PubMed ID: 25783402)
21. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Bouattour M; Soubrane O; de Gramont A; Faivre S
Trials; 2016 Nov; 17(1):563. PubMed ID: 27887632
[TBL] [Abstract][Full Text] [Related]
22. Marriage and fertility in long-term survivors of childhood, adolescent and young adult (AYA) high-grade sarcoma.
Yonemoto T; Takahashi M; Maru M; Tomioka A; Saito M; Araki Y; Tazaki M; Tsuchiya M; Iwata S; Kamoda H; Ishii T
Int J Clin Oncol; 2016 Aug; 21(4):801-807. PubMed ID: 26792434
[TBL] [Abstract][Full Text] [Related]
23. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
24. Ifosfamide in pediatric solid tumors.
Carli M; Passone E; Perilongo G; Bisogno G
Oncology; 2003; 65 Suppl 2():99-104. PubMed ID: 14586158
[TBL] [Abstract][Full Text] [Related]
25. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution.
Farhat R; Raad R; Khoury NJ; Feghaly J; Eid T; Muwakkit S; Abboud M; El-Solh H; Saab R
J Pediatr Hematol Oncol; 2013 Jul; 35(5):356-60. PubMed ID: 23042020
[TBL] [Abstract][Full Text] [Related]
26. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
Kebudi R; Cakir FB; Gorgun O; Agaoglu FY; Darendeliler E
Pediatr Hematol Oncol; 2013 Apr; 30(3):170-7. PubMed ID: 23484903
[TBL] [Abstract][Full Text] [Related]
27. Emerging therapeutic targets for synovial sarcoma.
Palmerini E; Paioli A; Ferrari S
Expert Rev Anticancer Ther; 2014 Jul; 14(7):791-806. PubMed ID: 24661286
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
[TBL] [Abstract][Full Text] [Related]
29. Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents.
Podda MG; Luksch R; Puma N; Gandola L; Morosi C; Terenziani M; Ferrari A; Casanova M; Spreafico F; Meazza C; Catania S; Schiavello E; Biassoni V; Chiaravalli S; Massimino M
Tumori; 2016; 102(1):84-8. PubMed ID: 26797935
[TBL] [Abstract][Full Text] [Related]
30. Systemic therapy for osteosarcoma and Ewing sarcoma.
Meyers PA
Am Soc Clin Oncol Educ Book; 2015; ():e644-7. PubMed ID: 25993235
[TBL] [Abstract][Full Text] [Related]
31. Standard chemotherapy for malignant bony tumors in children and young adults.
Rafique A; Kent PM
Curr Probl Cancer; 2013; 37(4):207-14. PubMed ID: 24238586
[No Abstract] [Full Text] [Related]
32. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
[TBL] [Abstract][Full Text] [Related]
33. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
34. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Terry SY; Abiraj K; Lok J; Gerrits D; Franssen GM; Oyen WJ; Boerman OC
J Nucl Med; 2014 Nov; 55(11):1849-55. PubMed ID: 25349221
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy in prevention of the recurrence of resectable cancer.
Bonadonna G; Tancini G; Rossi A; Gasparini M
Annu Rev Med; 1978; 29():149-75. PubMed ID: 206184
[No Abstract] [Full Text] [Related]
36. Surgical Treatment for Pneumothorax and Tumor-bronchial Fistula Secondary to Pulmonary Metastasis of Osteosarcoma in Pediatric and Adolescent Patients.
Kawakubo N; Hishiki T; Arakawa A; Nakajima M; Kumamoto T; Nakagawa K; Kawai A; Ogawa C
J Pediatr Hematol Oncol; 2022 Oct; 44(7):393-397. PubMed ID: 35091523
[TBL] [Abstract][Full Text] [Related]
37. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
[TBL] [Abstract][Full Text] [Related]
38. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
Marsh AM; Lo L; Cohen RA; Feusner JH
Pediatr Blood Cancer; 2012 Nov; 59(5):939-40. PubMed ID: 22492703
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
